English
The cardiac toxicity caused by Dox chemotherapy severely limits its clinical application and is also the main cause of late stage death in chemotherapy patients. At present, there is no effective treatment method. We analyzed 295 clinical samples from 132 chemotherapy patients and 163 individuals who underwent physical examinations and found a strong positive correlation between intestinal barrier damage and cardiac toxicity in chemotherapy patients. We have developed a novel oral and intestinal targeted protein nanomedicine by assembling membrane protein Amuc_1100 (obtained from intestinal bacteria), fluorinated polyetherimide, and hyaluronic acid. Compared with free Amuc_1100, protein nanomedicine exhibits good anti hydrolysis stability. The in vivo results indicate that protein nanomedicine can improve gut microbiota, increase the proportion of short chain fatty acid producing bacteria in the family, and further increase the levels of butyric acid and valeric acid, ultimately regulating gut microbiota and reducing Dox induced cardiac toxicity. Steady state repair of lymphocytes in the spleen and heart. Therefore, we believe that the integrity of the intestinal barrier plays an important role in the occurrence of chemotherapy-induced cardiac toxicity. Protective interventions targeting the intestinal barrier may have the potential to become a general clinical treatment plan for reducing doxorubicin induced cardiac toxicity.
